首页> 外文期刊>Leukemia >Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma
【24h】

Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma

机译:阵列比较基因组杂交定义的基因组得失与存活之间的相关性:确定1p31-32缺失是骨髓瘤的预后因素

获取原文
           

摘要

In this study, we correlated array-comparative genomic hybridization-defined abnormalities with survival in two different cohorts of patients treated with therapy based on high-dose melphalan with autologous stem-cell transplantation (64 from the Mayo Clinic and 67 from the University of Arkansas Medical School) and identified that several regions of genomic gains and losses were significantly associated with poorer survival. Three noncontiguous survival relevant regions covering 1p31-33 and two noncontiguous regions covering 20p12.3-12.1 were common between the two datasets. The prognostic relevance of these hotspots was validated in an independent cohort using fluorescent in situ hybridization, which showed that 1p31-32 loss is significantly associated with shorter survival (24.5 months versus 40 months, log-rank P-value=0.01), whereas 20p12 loss has a trend toward shorter survival (26.3 months versus 40 months, log-rank P-value=0.06). On multivariate analysis, 1p31-32 loss is an independent prognostic factor. On further analysis, the prognostic impact of 1p31-32 loss is due to shortening of post-relapse survival as there is no impact on complete response rates and progression-free survival.
机译:在这项研究中,我们将阵列比较基因组杂交定义的异常与两个不同队列的患者进行了相关性研究,这些患者接受了基于高剂量马法兰治疗的自体干细胞移植治疗(Mayo Clinic公司64名,阿肯色大学67名)医学院),并发现基因组得失的几个区域与较差的存活率显着相关。这两个数据集之间共有三个不连续的生存相关区域,分别覆盖1p31-33和两个不连续的生存区域,分别覆盖20p12.3-12.1。这些热点的预后相关性在使用荧光原位杂交的独立队列中得到验证,这表明1p31-32缺失与较短的生存时间显着相关(24.5个月对40个月,对数秩P值= 0.01),而20p12丢失的趋势是生存期较短(26.3个月对40个月,对数秩P值= 0.06)。在多变量分析中,1p31-32丢失是独立的预后因素。在进一步分析中,1p31-32丢失的预后影响是由于缩短了复发后生存期,因为对完全缓解率和无进展生存期没有影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号